Consistent patterns of expression of HLA class I free heavy chains in healthy individuals and raised expression in spondyloarthropathy patients point to physiological and pathological roles

Rheumatology

Volumn 45, Issue 11, 2006, Pages 1338-1344

  Raine, T ^a   Brown, D ^a   Bowness, P ^b   Hill Gaston, J S ^c   Moffett, A ^a   Trowsdale, J ^a   Allen, R L ^a  

^a Department of Pathology ^*  (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Ankylosing spondylitis; FHC; Free heavy chain; HLA B27; HLA G; MHC

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; HLA ANTIGEN CLASS 1; HLA B27 ANTIGEN;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD SAMPLING; CELL ACTIVATION; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLOW CYTOMETRY; HEAVY CHAIN; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MACROPHAGE; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; TROPHOBLAST; UPREGULATION; VOLUNTEER;

ADULT; ARTHRITIS, REACTIVE; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-B27 ANTIGEN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LEUKOCYTES; MACROPHAGE ACTIVATION; MACROPHAGES; MALE; MIDDLE AGED; SPONDYLARTHROPATHIES; TROPHOBLASTS;

EID: 33750201148     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kel305     Document Type: Article

References (48)

1. Raine T, Allen RL. MHC-I recognition by receptors on myelomonocytic cells: New tricks for old dogs? BioEssays 2005;27:542-50.
2. Allen RL, Raine T, Haude A, Trowsdale J, Wilson MI. Leukocyte receptor complex-encoded immunomodulatory receptors show differing specificity for alternative HLA-B27 structures. J Immunol 2001;167:5543-7.
3. Allen RL, O'Callaghan CA, McMichael AJ, Bowness P. Cutting edge: HLA-B27 can form a novel beta 2-mi1croglobulin-free heavy chain homodimer structure. J Immunol 1999;162:5045-8.
4. Cauli A, Dessole G, Mathieu A. HLA-B27 and free HLA class I heavy chains Ain ankylosing spondylitis. J Rheumatol 2003;30:1120: author reply 1120-1.
5. Cauli A, Dessole G, Fiorillo MT et al. Increased level of HLA-B27 expression in ankylosing spondylitis patients compared with healthy HLA-B27-positive subjects: A possible further susceptibility factor for the development of disease. Rheumatology 2002;41:1375-9.
6. Dangoria NS, DeLay ML, Kingsbury DJ et al. HLA-B27 misfolding is associated with aberrant intermolecular disulfide bond formation (dimerization) in the endoplasmic reticulum. J Biol Chem 2002; 277:23459-68.
7. Khare SD, Hansen J, Luthra HS, David CS. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. J Clin Invest 1996;98:2746-55.
8. Kollinberger S, Bird LA, Roddis M et al. HLA-B27 heavy chain homodimers are expressed in HLA-B27 transgenic rodent models of spondyloarthritis and are ligands for paired Ig-like receptors. J Immunol 2004;17:1699-710.
9. Kollnberger S, Bird L, Sun MY et al. Cell-surface expression and immune receptor recognition of HLA-B27 homodimers. Arthritis Rheum 2002;46:297282,
10. Tsai WC, Chen CJ, Yen JH et al. Free HLA class I heavy chain-carrying monocytes - a potential role in the pathogenesis of spondyloarthropathies. J Rheumatol 2002;29:966-72.
11. Pamer E, Cresswell P. Mechanisms of MHC class I - restricted antigen processing. Amin Rev Immunol 1998;16:323-58.
12. Machold RP, Ploegh HL. Intermediates in the assembly and degradation of class I major histocompatibility complex (MHC) molecules probed with free heavy chain-specific monoclonal antibodies. J Exp Med 1996;184:2251-9.
13. Carreno BM, Hansen TH. Exogenous peptide ligand influences the expression and half-life of free HLA class I heavy chains ubiquitously detected at the cell surface. Eur J Immunol 1994;24:1285-92.
14. Parker KC, DiBrino M, Hull L, Coligan JE. The beta 2-microglobulin dissociation rate is an accurate measure of the stability of MHC class I heterotrimers and depends on which peptide is bound. J Immunol 1992;149:1896-904.
15. Martayan A, Fiscella M, Setini A et al. Conformation and surface expression of free HLA-CW1 heavy chains in the absence of beta 2-microglobulin. Hum Immunol 1997;53:23-33.
16. Demaria S, Schwab R, Gottesman SR, Bushkin Y. Soluble beta 2-microglobulin-free class I heavy chains are released from the surface of activated and leukemia cells by a metalloprotease. J Biol Chem 1994;269:6689-94.
17. Pickl WF, Holter W, StockI J, Majdic O, Knapp W. Expression of beta 2-microglobulin-free HLA class 1 alpha-chains on activated T cells requires internalization of HLA class I heterodimers. Immunology 1996;88:104-9.
18. Schnabl E, Stockinger H, Majdic O et al. Activated human T lymphocyte express MHC class I heavy chains not associated with beta 2-microglobulin. J Exp Med 1990;171:1431-42.
19. Madrigal JA, Belich MP, Benjamin RJ et al. Molecular definition of a polymorphic antigen (LA45) of free HLA-A and -B heavy chains found on the surfaces of activated B and T cells. J Exp Med 1991;174:1085-95.
20. Demaria S, Bushkin Y. CD8 and beta 2-microglobulin-free MHC class I molecules in T cell immunoregulation. Int J Clin Lab Res 1993;23:61-9.
21. Santos SG, Powis SJ, Arosa FA. Misfolding of major histocompatibility complex class I molecules in activated T cells allows cis-interactions with receptors and signaling molecules and is associated with tyrosine phosphorylation. J Biol Chem 2004;279-53062-70.
22. Marozzi A, Meneveri R, De Santis C et al. Expression of distinct conformations of free HLA-Cw4 heavy chains in transfected neuroblastoma cells. Immunogenetics 1996;43:289-95.
23. Capps GG, Robinson BE, Lewis KD, Zuniga MC. In vivo dimeric association of class I MHC heavy chains. Possible relationship to class I MHC heavy chain-beta 2-microglobulin dissociation. J Immunol 1993;151:159-69.
24. Tran TM, Satumtira N, Dorris ML et al. HLA-B27 in transgenic rats forms disulfide-linked heavy chain oligomers and multimers that bind to the chaperone BiP J Immunol 2004;172:5110-9.
25. Gonen-Gross T, Gazit R, Achdout H et al. Special organization of the HLA-G protein on the cell surface. Hum Immunol 2003; 64:1011-6.
26. Gonen-Gross T, Achdout H, Gazit R et al. Complexes of HLA-G protein on the cell surface are important for leukocyte Ig-like receptor-1 function. J Immunol 2003;171:1343-51.
27. Bowness P, Zaccai N, Bird L, Jones EY. HLA-B27 and disease pathogenesis: new structural and functional insights. Expert Rev Mol Med 1999:1-10.
28. Colbert RA. The immunobiology of HLA-B27: Variations on a theme. Curr Mol Med 2004;4:21-30.
29. Setini A, Beretta A, De Santis C et al. Distinctive features of the alpha 1-domain alpha helix of HLA-C heavy chains free of beta 2-microglobulin. Hum Immunol 1996;46:69-81.
30. Kingsbury DJ, Mear JP, Witte DP, Taurog JD, Roopenian DC, Colbert RA. Development of spontaneous arthritis in beta2- microglobulin-deficient mice without expression of HLA-B27: Association with deficiency of endogenous major histocompatibility complex class I expression. Arthritis Rheum 2000;43:2290-6.
31. Burrows TD, King A, Loke YW. Expression of integrins by human trophoblast and differential adhesion to laminin or fibronectin. Hum Reprod 1993;8:475-84.
32. Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, DeMars R. A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990;248:220-3.
33. Allen RL, Gillespie GM, Hall F et al. Multiple T cell expansions are found in the blood and synovial fluid of patients with reactive arthritis. J Rheumatol 1997;24:1750-7.
34. Maziarz RT, Fraser J, Strominger JL, Burakoff SJ. The human HLA-specific monoclonal antibody W6/32 recognizes a discontinuous epitope within the alpha 2 domain of murine H-2Db. Immunogenetics 1986;24:206-8
35. Stam NJ, Vroom TM, Peters PJ, Pastoors EB, Ploegh HL. HLA-A-and HLA-B-specific monoclonal antibodies reactive with free heavy chains in western blots, in formalin-fixed, paraffin-embedded tissue sections and in cryo-immuno-electron microscopy. Int Immunol 1990;2:113-25.
36. Sernee MF, Ploegh HL, Schust DI. Why certain antibodies crossreact with HLA-A and HLA-G: Epitope mapping of two common MHC class I reagents. Mol Immunol 1998;35:177-88.
37. Lan CC, Tsai WC, Wu CS, Yu CL, Yu HS. Psoriatic patients with arthropathy show significant expression of free HLA class I heavy chains on circulating monocytes: A potential role in the pathogenesis of psoriatic arthropathy. Br J Dermatol 2004; 151:24-31.
38. Sesma L, Galocha B, Vazquez M et al. Qualitative and quantitative differences in peptides bound to HLA-B27 in the presence of mouse versus human tapasin define a role for tapasin as a size-dependent peptide editor. J Immunol 2005;174:7833-44.
39. Boyson JE, Erskine R, Whitman MC et al. Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci USA 2002;99:16180-5.
40. Petroff MG, Sedlmayr P, Azzola D, Hunt JS. Decidual macrophages are potentially susceptible to inhibition by class Ia and class Ib HLA molecules. J Reprod Immunol 2002;56:3-17.
41. Shiroishi M, Kuroki K, Ose T et al. Efficient leukocyte Ig-like receptor signaling and crystal structure of disulfide-linked HLA-G dimer. J Biol Chem 2006;281:10439-47.
42. King A, Hiby SE, Verma S, Burrows T, Gardner L, Loke YW. Uterine NK cells and trophoblast HLA class I molecules. Am J Reprod Immunol 1997;37:459-62.
43. Simon AK, Scipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994;91:8562-6.
44. Melillo L, Cascavilla N, Lombardi G, Carotenuto M, Musto P. Prognostic relevance of serum beta 2-microglobulin in acute myeloid leukemia. Leukemia 1992;6:1076-8.
45. Baeten D, Kruithof E, Van den Bosch F et al. Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: Histologic findings in eight patients from an open-label pilot study. Arthritis Rheum 2001;44:186-95.
46. De Keyser F, Baeten D, Van den Bosch F, Kruithof E, Mielants H, Veys EM. Infliximab in patients who have spondyloarthropathy: Clinical efficacy, safety, and biological immunomodulation. Rheum Dis Clin North Am 2003;29:463-79.
47. Baeten D, Kruithof E, De Rycke L et al. Diagnostic classification of spondylarthropathy and rheumatoid arthritis by synovial histopathology: a prospective study in 154 consecutive patients. Arthritis Rheum 2004;50:2931-41.
48. De Rycke L, Baeten D, Foell D et al. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. J Pathol 2005;206:17-27.